Quoin Pharmaceuticals, Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $22.7M
- Price
- $4.72
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.62%
- Volume
- 103.8K
About
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Quick stats
Shares outstanding4.8M
Computed float4.5M
Float / shares93.1%
Cash runway (months)34.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001671502
Websitehttps://quoinpharma.com
AI Summary
AI-generated1/23
minorbullishoperations update
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Quoin Pharmaceuticals announced that a peer-reviewed paper on QRX003, its investigational topical serine protease inhibitor lotion for Netherton Syndrome, has been accepted for publication in Dermatology and Therapy.
The paper includes a compassionate-use case report from Professor Alan Irvine describing fully healed skin, complete elimination of itch, and reduced medication needs in a pediatric patient.
This adds to previously reported positive interim Phase 2/3 results, in which four of six patients (66.7%) hit the primary endpoint, though no new clinical data were disclosed in this release.